Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mol Med Rep ; 20(5): 4645-4653, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31545496

RESUMO

Previous studies have demonstrated that microRNA (miR)­146a is involved in the inflammatory response of atopic dermatitis (AD). The aim of the present study was to investigate the expression of miR­146a in the serum of patients with AD and in skin lesions of AD animal models. In addition, we aimed to predict and verify the target genes of miR­146a. miR­146a expression was measured in AD patient serum via reverse transcription­quantitative PCR. T­helper (Th)1 [CD4+; interferon (IFN)­Î³+] and Th2 [CD4+; interleukin (IL)­4+] expression in peripheral blood mononuclear cells was evaluated using flow cytometry. Following the establishment of a 2,4­dinitrofluorobenzene­induced C57BL/6 mouse AD model, Th1 (CD4+IFN­Î³+) and Th2 (CD4+IL­4+) expression was analyzed in murine spleen cells via flow cytometry. Plasmids were transfected into 293T cells and at 48 h post­transfection, cells were analyzed using a luciferase assay system. The results revealed that the AD group had a significantly lower Th1/Th2 ratio and a significantly higher miR­146a expression compared with the control group (P<0.05). Furthermore, a decreased Th1/Th2 ratio and a significantly increased miR­146a expression were observed in the model group compared with the control group (P<0.01). We also conducted a dual­luciferase assay to determine whether small ubiquitin­related modifier 1 (SUMO1) if the target gene of miR­146a. We observed a ~30% decrease in the relative luciferase activity in cells containing the 3'­untranslated region of SUMO1 + miR­146a). The results of the luciferase assay indicated that may be a direct mRNA target of miR­146a; however, the quantification of band density of SUMO1 expression following western blotting did not significantly differ. The development of animal models in AD research is of vital importance. The results revealed that miR­146a may be a potential regulator involved in the pathogenesis of AD. Furthermore, the current study determined that miR­146a could be a valuable marker of AD and thus, may be applied in the development of therapeutic strategies for treating AD.

2.
Iran J Allergy Asthma Immunol ; 18(4): 347-357, 2019 Aug 17.
Artigo em Inglês | MEDLINE | ID: mdl-31522443

RESUMO

Atopic dermatitis (AD) is a chronic, recurrent skin condition resulting from both genetic and environmental factors. In recent decades, the prevalence of AD has increased considerably in some countries. However, given that the role of genetics is unlikely to have changed over this short period, the increased prevalence is more likely to be explained by changes in environmental and maternal factors. The aim of this review is to comprehensively summarize the various factors impacting AD incidence in offspring and provide guidance for primary prevention. Recent research has demonstrated that environmental and climate factors, maternal history of allergies, gestational diabetes, and stress play essential roles in increasing the risk of AD in infants. Some factors have protective effects against the incidence of AD, including probiotic supplementation, fish intake, and moisturizers. This review also considers fundamental research into AD prevalence and factors that in the past were mistakenly thought to affect that prevalence, such as caesarean section and antigen avoidance. The potential influence of these factors on infant AD incidence remains inconclusive and needs further study. Furthermore, infants with a family history of atopic disease may benefit from early weaning or reduced breastfeeding duration.

3.
Biomed Res Int ; 2019: 7465272, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31355279

RESUMO

In parallel with the prevalence metabolic syndrome, nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in most countries. It features a constellation of simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even hepatocellular carcinoma. There are no approved drugs for effective management of NAFLD and NASH. Jianpi Huoxue formula (JPHX) mainly consists of Atractylodes macrocephal (Baizhu), Salvia miltiorrhiza (Danshen), Rasux Paeonia Alba (Baishao), Rhizoma Alismatis (Zexie), and Fructus Schisandrae Chinensis (Wuweizi), which may have beneficial effects on NAFLD. The aim of the study was to identify the effect of JPHX on NAFLD. A NAFLD model was induced by methionine-choline-deficient food (MCD) in Wistar rats and orally administered with simultaneous JPHX, once a day for 8 weeks. Hepatocellular injury, lipid profile, inflammation, fibrosis, and apoptosis were evaluated. The results showed that JPHX significantly decreased the abnormal serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels compared with the MCD model (P<0.05). Furthermore, JPHX protected MCD diet-fed rats from accumulation of hepatic triglycerides (TG) and total cholesterol (TC). Histological examination demonstrated that JPHX noticeably normalized the NAFLD activity score (NAS). Moreover, JPHX ameliorated liver inflammation by decreasing TNF-α levels and reduced collagen and matrix metalloproteinases in MCD diet-fed rats. In addition, JPHX prevented rats from MCD-induced cellular apoptosis, as suggested by TUNEL staining, and suppressed the activation of caspase 3 and 7 proteins. JPHX also inhibited the phosphorylation of JNK. In conclusion, JPHX exhibited a hepatoprotective effect against NAFLD in an MCD experimental model.


Assuntos
Medicamentos de Ervas Chinesas/farmacologia , Alimentos Formulados/efeitos adversos , Fígado , Hepatopatia Gordurosa não Alcoólica , Animais , Colina , Fígado/metabolismo , Fígado/patologia , Masculino , Metionina , Hepatopatia Gordurosa não Alcoólica/metabolismo , Hepatopatia Gordurosa não Alcoólica/patologia , Hepatopatia Gordurosa não Alcoólica/prevenção & controle , Ratos , Ratos Wistar
4.
BMC Infect Dis ; 19(1): 506, 2019 Jun 10.
Artigo em Inglês | MEDLINE | ID: mdl-31182059

RESUMO

BACKGROUND: Scalp mycosis is often caused by dermatophytes and was so called tinea capitis. There is no published report caused by Aspergillus protuberus. We report a rare case of kerion-type scalp mycosis caused by A. protuberus. CASE PRESENTATION: A 5-year-old girl developed pyogenic mass with pain for 8 days and got a fever for 2 days prior to admission. Surgical incision and drainage of the mass, intravenous cefuroxime and metronidazole in the local hospital aggravated the skin lesions. Species identification was performed by observation of morphologic and biochemical characteristicsand sequencing of the internal transcribed spacer (ITS) and ß-tubulin (BT2). Treatment with oral and topical antifungal agents was effective with no relapse during the six months of clinical follow-up. CONCLUSIONS: Aspergillusis a opportunistic pathogenic fungus and its infection occurs mostly in patients with underlying conditions and immunocompromised statuses. So far no report of kerion-type scalp infection has been reported. The first case of kerion-type scalp mycosis caused by A. protuberus was described to highlight the importance of mycological examination that helps to recognize rare pathogenic fungi. Any boggy lesion with hair loss over the scalp and non-responsive to antibiotics should be suspected as resulting from fungal infection, and mycological examination should be performed, especially in children.


Assuntos
Aspergillus/isolamento & purificação , Micoses/diagnóstico , Couro Cabeludo/patologia , Antifúngicos/uso terapêutico , Aspergillus/classificação , Pré-Escolar , Feminino , Humanos , Hospedeiro Imunocomprometido , Micoses/tratamento farmacológico , Micoses/microbiologia , Filogenia , Couro Cabeludo/microbiologia
6.
Mol Med Rep ; 16(5): 7175-7184, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28944829

RESUMO

The thymus is critical in establishing and maintaining the appropriate microenvironment for promoting the development and selection of T cells. The function and structure of the thymus gland has been extensively studied, particularly as the thymus serves an important physiological role in the lymphatic system. Numerous studies have investigated the morphological features of thymic involution. Recently, research attention has increasingly been focused on thymic proteins as targets for drug intervention. Omics approaches have yielded novel insights into the thymus and possible drug targets. The present review addresses the signaling and transcriptional functions of the thymus, including the molecular mechanisms underlying the regulatory functions of T cells and their role in the immune system. In addition, the levels of cytokines secreted in the thymus have a significant effect on thymic functions, including thymocyte migration and development, thymic atrophy and thymic recovery. Furthermore, the regulation and molecular mechanisms of stress­mediated thymic atrophy and involution were investigated, with particular emphasis on thymic function as a potential target for drug development and discovery using proteomics.


Assuntos
Citocinas/metabolismo , Transdução de Sinais , Linfócitos T/metabolismo , Timo/metabolismo , Animais , Movimento Celular , Humanos , Fosfatidilinositol 3-Quinase/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Linfócitos T/citologia , Linfócitos T/imunologia , Linfócitos T Reguladores/citologia , Linfócitos T Reguladores/metabolismo , Serina-Treonina Quinases TOR/metabolismo , Timo/citologia
7.
J Dermatolog Treat ; 28(3): 246-250, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-27538116

RESUMO

Atopic eczema (AE), or atopic dermatitis, is a common inflammatory skin disease. As conventional medicines for moderate and severe AE patients have been reported to be associated with unwanted side effects, many patients with AE have sought other therapies. Chinese herbal medicine (CHM) is one of the most commonly used complementary therapies with a long history of being applied for the treatment of AE. Clinical evidence for CHM for AE in systematic reviews and randomised controlled trials (RCTs) published from 2013 to 2016 was reviewed. Findings from the Cochrane systematic review suggested that oral use of a CHM formulation may improve health-related quality of life (HRQoL) of children with moderate or severe AE. The benefit on improvement of AE requires further high-quality clinical studies.


Assuntos
Dermatite Atópica/tratamento farmacológico , Medicamentos de Ervas Chinesas/uso terapêutico , Criança , Ensaios Clínicos como Assunto , Dermatite Atópica/patologia , Medicamentos de Ervas Chinesas/efeitos adversos , Humanos , Miocárdio/metabolismo , Miocárdio/patologia , Qualidade de Vida , Índice de Gravidade de Doença , Baço/metabolismo , Baço/patologia
8.
Front Immunol ; 6: 494, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26539191

RESUMO

CD8(+)CD122(+) T-cells have been traditionally described as antigen-specific memory T-cells that respond to previously encountered antigens more quickly and vigorously than their naïve counterparts. However, mounting evidence has demonstrated that murine CD8(+)CD122(+) T-cells exhibit a central memory phenotype (CD44(high)CD62L(high)), regulate T cell homeostasis, and act as regulatory T-cells (Treg) by suppressing both autoimmune and alloimmune responses. Importantly, naturally occurring murine CD8(+)CD122(+) Tregs are more potent in immunosuppression than their CD4(+)CD25(+) counterparts. They appear to be acting in an antigen-non-specific manner. Human CD8(+)CXCR3(+) T-cells are the equivalent of murine CD8(+)CD122(+) Tregs and also exhibit central memory phenotypes. In this mini-review article, we will summarize recent progresses in their phenotypes, homeostatic expansion, antigen-specificity, roles in the suppression of alloimmune and autoimmune responses, and the mechanisms underlying their inhibitory function.

9.
Complement Ther Med ; 23(5): 644-51, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26365443

RESUMO

BACKGROUND: More randomised control trials are required to assess the efficacy of traditional Chinese medicine. This multi-centre, randomised, assessor-blind, controlled study assessed the efficacy of the Chinese herbal formula Pei Tu Qing Xin Tang (PTQXT) for treating patients with atopic dermatitis (AD). METHODS: Patients aged 5-25 years with moderate-to-severe AD were randomised to receive a 12-week treatment involving either oral administration of PTQXT; oral administration of PTQXT combined with an external application of Chinese herbs; or oral administration of antihistamine and a placebo of PTQXT pills added to topical 1% mometasone furoate. The primary end-point measure was the change in the Scoring Atopic Dermatitis Index (SCORAD) at the end of the observation period, and secondary end-points included quality of life (QOL). The outcomes were evaluated at baseline, then every 4 weeks from week 4 to week 12 and every 8 weeks from week 12 to week 36. RESULTS: Two hundred and seventy-five patients were recruited. During the 12-week treatment period, up to the primary end-point, the mean SCORAD decreased gradually in all three groups. At week 28 and week 36, there was a significantly greater decrease in the mean SCORAD for the Chinese herbal medicine-treated groups than for the control group (at week 28, P=0.002 and P=0.036, respectively; at week 36, P<0.001 and P=0.002, respectively). At week 36, the difference in QOL scores showed a significantly greater improvement in both Chinese herbal medicine-treated groups than in the control group (P<0.001 and P<0.001, respectively). CONCLUSIONS: PTQXT is effective in decreasing the severity of the disease and improving the QOL in patients with moderate-to-severe AD. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR-TRC-08000156.


Assuntos
Dermatite Atópica/tratamento farmacológico , Medicamentos de Ervas Chinesas/uso terapêutico , Administração Oral , Administração Tópica , Adolescente , Adulto , Criança , Medicamentos de Ervas Chinesas/administração & dosagem , Medicamentos de Ervas Chinesas/efeitos adversos , Feminino , Humanos , Masculino , Adesão à Medicação , Placebos , Qualidade de Vida , Resultado do Tratamento , Adulto Jovem
10.
Sci Rep ; 5: 12844, 2015 Aug 07.
Artigo em Inglês | MEDLINE | ID: mdl-26248949

RESUMO

The rat is an important alternative for studying human pathology owing to certain similarities to humans. Glycomic studies on rat serum have revealed that variations in the N-glycans of glycoproteins correlated with disease progression, which is consistent with the findings in human serum. Therefore, we comprehensively characterized the rat serum N-glycome using microfluidic chip-LC-ESI-QTOF MS and MS/MS techniques. In total, 282 N-glycans, including isomers, were identified. This study is the first to present comprehensive profiling of N-glycans containing O-acetylated sialic acid, among which 27 N-glycans are novel. In addition, the co-existence of N-acetylneuraminic acid (NeuAc) and N-glycolylneuraminic acid (NeuGc) in a single N-glycan ('mixed' N-glycan) was detected and represents a new type of N-glycan in rat serum. The existence of O-acetylated sialic acid is the characteristic feature of rat serum that distinguishes it from mouse and human sera. Comparisons between the rat, mouse, and human serum glycomes revealed that the rat glycome is more similar to that of human sera than to that of mouse sera. Our findings highlight the similarities between the glycomic profile of rat and human sera and provided important selection criteria for choosing an appropriate animal model for pathological and pharmacological studies.


Assuntos
Polissacarídeos/química , Soro/química , Acetilação , Animais , Cromatografia Líquida/métodos , Glicômica/métodos , Humanos , Masculino , Camundongos , Técnicas Analíticas Microfluídicas/métodos , Microfluídica/métodos , Ácido N-Acetilneuramínico/química , Ácidos Neuramínicos/química , Ratos , Ratos Sprague-Dawley , Ácidos Siálicos/química , Espectrometria de Massas em Tandem/métodos
11.
Trials ; 16: 294, 2015 Jul 07.
Artigo em Inglês | MEDLINE | ID: mdl-26149448

RESUMO

BACKGROUND: Atopic eczema or atopic dermatitis is a chronic inflammatory skin disease. Current conventional medical treatment for moderate and severe atopic eczema is not satisfactory. There is promising evidence derived from randomised clinical trials to support the clinical use of Chinese herbal medicine in the management of atopic eczema. However, the available evidence is compromised by the high risk of bias associated with most of the included trials. Therefore, well-designed and adequately powered randomised clinical trials are needed. The primary aim of this trial is to evaluate the efficacy and safety of oral ingestion of an oral Chinese herbal formula (Pei Tu Qing Xin granules; PTQX) in children aged between 6 and 16 years with moderate to severe atopic eczema. METHODS/DESIGN: We have designed a randomised, double-blind, placebo-controlled, two-arm, parallel clinical trial with 12 weeks of treatment and a 4-week follow-up period. A pilot study with 30 participants will be conducted at the RMIT University in Australia to determine the feasibility of the full-scale randomised clinical trial (N = 124). Eczema Area and Severity Index score will be the primary outcome. Secondary outcome measures include change in symptoms using the Patient-Oriented Eczema Measure, the Children's Dermatology Life Quality Index and the use of concomitant medicines. Safety parameters include report of adverse events and pathology tests during the trial period. DISCUSSION: Key elements for conducting a high-quality randomised clinical trial have been addressed in this protocol. Findings from the proposed trial will provide critical evidence regarding Chinese herbal medicine treatment for atopic eczema. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry Identifier: ACTRN12614001172695. Date of Registration: 7 November 2014.


Assuntos
Dermatite Atópica/tratamento farmacológico , Fármacos Dermatológicos/uso terapêutico , Medicamentos de Ervas Chinesas/uso terapêutico , Pele/efeitos dos fármacos , Adolescente , Fatores Etários , Criança , Protocolos Clínicos , Dermatite Atópica/diagnóstico , Fármacos Dermatológicos/efeitos adversos , Método Duplo-Cego , Medicamentos de Ervas Chinesas/efeitos adversos , Estudos de Viabilidade , Feminino , Humanos , Masculino , Projetos Piloto , Projetos de Pesquisa , Índice de Gravidade de Doença , Pele/patologia , Fatores de Tempo , Resultado do Tratamento , Vitória
12.
Health Qual Life Outcomes ; 11: 212, 2013 Dec 21.
Artigo em Inglês | MEDLINE | ID: mdl-24359229

RESUMO

BACKGROUND: Zheng represents pattern differentiation in Traditional Chinese Medicine (TCM), as the basic unit and a key concept in TCM therapeutic theory, is based on the physiology and pathology of TCM. None of the outcome measurements of atopic dermatitis (AD) are Zheng-specific. The effectiveness of TCM is likely to be underestimated without a Zheng-related symptom-specific instrument. The aim of this study was to develop an instrument for measuring the Zheng-related symptom-specific status of patients with AD. METHODS: We followed standard methodology to develop the instrument, including item generation and selection, item reduction and presentation, and pretesting, and recruited 188 patients with AD involved in a six-center randomized-controlled trial (ChiCTR-TRC-08000156) to validate the questionnaire. We conducted construct validity, reliability, and responsiveness analysis. The standardized effect size (SES) and standardized response mean (SRM) were used to calculate the responsiveness of additional items and the total score for the rating items. RESULTS: ZRADSQ has 15 items, with 12 rating items and 3 additional items. The 12 rating items fall within three domains: AD symptoms (n = 6 items); Heat (n = 4 items) and Mood (n = 2 items). Confirmatory factor analysis provided good support for a three-factor model (d.f. = 51, x2=97.11, RMSEA = 0.07, CFI = 0.96), and the Pearson's correlation coefficient between ZRADSQ and Severity Scoring of Atopic Dermatitis (SCORAD) was 0.40 (P < 0.001). The reliability was also good, with a Cronbach's alpha value for ZRADSQ of 0.84, a split-half coefficient of 0.75, and a test-retest reliability coefficient of 0.98. The standardized effect size and standardized response mean were close to or larger than 1, which indicated moderate to good responsiveness. CONCLUSIONS: The ZRADSQ demonstrates promising reliability, validity, and responsiveness. It can be used to determine whether Zheng-specific or symptom-specific treatments relieve the symptom that is most bothersome the patient.


Assuntos
Dermatite Atópica/psicologia , Medicina Tradicional Chinesa , Avaliação de Resultados da Assistência ao Paciente , Qualidade de Vida/psicologia , Inquéritos e Questionários/normas , Adolescente , Adulto , Criança , Análise Fatorial , Feminino , Humanos , Masculino , Adulto Jovem
13.
J Am Acad Dermatol ; 69(2): 295-304, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23759835

RESUMO

BACKGROUND: Atopic dermatitis (AD) is a chronic, itching skin disease, and conventional therapies offer inadequate symptom management. Patients with AD are increasingly turning to Chinese medicine. OBJECTIVE: We systematically evaluated the clinical evidence of the efficacy and safety of oral Chinese herbal medicine for AD. METHODS: Searches were conducted on major electronic databases using the following key words: "randomized controlled trials," "atopic dermatitis," "traditional Chinese medicine," "traditional East Asian medicine," "herbal medicine," "Chinese herbal drugs," "medicinal plants," "phytotherapy," "Kampo medicine," and "Korean traditional medicine." The results were screened to include English/Chinese randomized controlled trials. A metaanalysis was conducted on suitable outcome measures. RESULTS: Seven randomized controlled trials were included (1 comparing Chinese herbal medicine and Western medicine with Western medicine alone; 6 comparing Chinese herbal medicine with placebo). Combined Chinese herbal medicine with Western medicine was superior to Western medicine alone. Three placebo controlled trials showed significant treatment efficacy and 2 showed significantly reduced concurrent therapy with Chinese herbal medicine. No abnormalities in safety profile or severe adverse events were reported. LIMITATIONS: A metaanalysis of all included studies could not be conducted because of study heterogeneity. CONCLUSIONS: Chinese herbal medicine significantly improved symptom severity of AD and was reported as well tolerated. However, the poor quality of studies did not allow for valid conclusions to support its tolerability and routine use. Additional studies addressing the methodologic issues are warranted to determine the therapeutic benefit of Chinese herbal medicine for AD.


Assuntos
Dermatite Atópica/tratamento farmacológico , Medicamentos de Ervas Chinesas/uso terapêutico , Satisfação do Paciente/estatística & dados numéricos , Dermatite Atópica/diagnóstico , Feminino , Humanos , Masculino , Fitoterapia/métodos , Prognóstico , Qualidade de Vida , Ensaios Clínicos Controlados Aleatórios como Assunto , Medição de Risco , Resultado do Tratamento
14.
BMJ Open ; 3(12): e003906, 2013 Dec 30.
Artigo em Inglês | MEDLINE | ID: mdl-24381256

RESUMO

INTRODUCTION: Atopic dermatitis is a chronic, inflammatory skin rash that greatly affects quality of life. The current therapies are inadequate in managing atopic dermatitis and often have associated adverse effects or drug tolerance development. Chinese medicine is expected to have promising prospects in the management of atopic dermatitis and recent studies have shown encouraging results. This study aims to evaluate the efficacy and safety of a newly formulated Chinese herbal formula, RMIT Chinese Medicine-106 (RCM-106), in the management of moderate-to-severe atopic dermatitis in children aged 6-18 years. METHODS: The study is a randomised, double-blind, placebo-controlled, parallel-armed clinical trial. Participant, investigator and assessors will remain blinded to the treatment assignment until after the study has been completed. After a 2-week run-in period, 90 participants will be randomised, using block randomised sequences generated by computer, to receive either RCM-106 or matching placebo capsules, twice daily, for a treatment period of 8 weeks and followed up for 4 weeks. Primary outcome measures include the evaluation of disease severity and extent using two validated scoring instruments-Scoring Atopic Dermatitis (SCORAD) and Patient-Oriented Scoring Atopic Dermatitis (PO-SCORAD). Secondary outcome measures include the evaluation of quality of life using the Children's Dermatology Life Quality Index (CDLQI); occurrence of adverse events and total usage of other therapies as recorded in the participants' daily diary and laboratory studies which include eosinophil count, total IgE, full blood count and liver and kidney function tests. Intention-to-treat analysis will be applied to all data analyses. ETHICS AND DISSEMINATION: This trial has received human ethics approval from the Human Research Ethics Committee (HREC) of RMIT University (Project number 15/12). The study findings will be published in peer-reviewed journals and presented at the national and international conferences. TRIAL REGISTRATION: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12612001181897. TGA CTN Scheme: Trial number 2012/0713; Protocol number 15/12.

15.
Nan Fang Yi Ke Da Xue Xue Bao ; 32(2): 230-3, 2012 Feb.
Artigo em Chinês | MEDLINE | ID: mdl-22381765

RESUMO

OBJECTIVE: To investigate serum cortisol level and glucocorticoid receptors (GR) mRNA expression in peripheral blood mononuclear cells (PBMCs) in patients with severe alopecia areata and liver-kidney deficiency syndrome and their involvement in the pathogenesis of severe alopecia areata. METHODS: In 32 patients with severe alopecia areata, serum cortisol levels were measured by chemiluminescence assay and GR mRNA expression in the PBMCs was detected using reverse transcription real-time fluorescence quantitative PCR before and after treatment, with 20 normal subjects serving as the controls. RESULTS: Serum cortisol level showed no significant difference between the cases and the normal controls (P>0.05). The expression of GR mRNA in the PBMCs was significantly lower in the patients than in the normal controls (P<0.05). The expression of GR mRNA was even lower after treatments in patients with alopecia areata (P<0.01). CONCLUSIONS: GC-GR disorder exists in severe alopecia areata. A decreased GR mRNA expression in the PBMCs can be involved in the pathogenesis of severe alopecia areata, and such pathological changes at the receptor and genetic levels might also serve as the microscopic basis of liver-kidbey deficiency syndrome in severe alopecia areata.


Assuntos
Alopecia em Áreas/sangue , Hidrocortisona/sangue , Medicina Tradicional Chinesa , Receptores de Glucocorticoides/metabolismo , Adulto , Estudos de Casos e Controles , Diagnóstico Diferencial , Feminino , Humanos , Leucócitos Mononucleares/metabolismo , Masculino , Pessoa de Meia-Idade , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Receptores de Glucocorticoides/genética , Adulto Jovem
16.
Zhongguo Zhong Yao Za Zhi ; 37(18): 2782-5, 2012 Sep.
Artigo em Chinês | MEDLINE | ID: mdl-23285933

RESUMO

OBJECTIVE: To evaluate the clinical adverse drug reactions (ADR) of Shuxuetong Injection (SXTI) comprehensively for its proper use and post-marketing reevaluation. METHOD: Electronic searching of the online Chinese and English medical databases were carried out from their inception to Feb. 2012, studies were screened and data were extracted according to inclusion and exclusion criteria; total number of ADR were calculated by study type respectively, ADR incidence rate was calculated by number of ADRs in experimental arm of clinical trials with control groups divided by total number of experimental groups. RESULT: Eighty and eight papers published concerning ADRs report of SXTI were included, including 65 clinical trials, 20 case reports, and 3 ADRs surveillance or analysis report. 174 ADRs were reported, mainly in circulation system, nervous system, the digestive system, skin and appendages. Adverse reaction type is mainly rash (44.3%) and the digestive system response (23.0%). The incidence rate calculated by data extracted from 65 clinical trials was 4.3%. CONCLUSION: Allergic reaction is the most common ADR type of SXTI. Incidence rate of different studies varies, so a rigorously designed prospectively ADR surveillance study is needed to reevaluate its incidence rate, and analyze reasons of the heterogeneity. Information concerning ADR in literatures is always absent, the quality of reporting is relative poor, thus it is suggested that active, standardized, and systematic ADR reporting should be focused on in clinical trials.


Assuntos
Tratamento Farmacológico , Medicamentos de Ervas Chinesas/efeitos adversos , Sistemas de Notificação de Reações Adversas a Medicamentos , Ensaios Clínicos como Assunto , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Medicamentos de Ervas Chinesas/administração & dosagem , Humanos
17.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 28(10): 900-2, 2008 Oct.
Artigo em Chinês | MEDLINE | ID: mdl-19123327

RESUMO

OBJECTIVE: To investigate the regulatory effect of procyanidins (PC) on the expressions of Th1 type cytokines (IFN-gamma and IL-12) and the transcription factor T-bet mRNA in peripheral blood mononuclear cell (PBMC) in patients with alopecia areata (AA). METHODS: Above-mentioned expressions were detected using RT-PCR technique in 20 AA patients (8 of mild and 12 of severe degree) and 10 healthy subjects after phytoaemagglutinin (PHA) or PHA + PC stimulation. RESULTS: After being stimulated by PHA and PHA + PC, in patients with severe AA, the expression of T-bet mRNA was 0.581 +/- 0.148 and 0.419 +/- 0.113 respectively; that of IFN-gamma mRNA, 0.689 +/- 0.219 and 0.430 +/- 0.162; and that of IL-12 mRNA, 0.198 +/- 0.056 and 0.136 +/- 0.035, respectively. As compared with those before stimulation, the respective difference was statistically significant (P < 0.05). CONCLUSIONS: PC can inhibit the expressions of Th1 type cytokines and transcription factor T-bet in PBMC of severe AA patients, and reverse the Th1 responses. The authors offered that it maybe part of the acting mechanism of pine needle for treatment of AA.


Assuntos
Alopecia em Áreas/tratamento farmacológico , Interferon gama/genética , Interleucina-12/genética , Leucócitos Mononucleares/efeitos dos fármacos , Proantocianidinas/administração & dosagem , Proteínas com Domínio T/genética , Adolescente , Adulto , Alopecia em Áreas/genética , Alopecia em Áreas/imunologia , Estudos de Casos e Controles , Células Cultivadas , Expressão Gênica/efeitos dos fármacos , Humanos , Interferon gama/imunologia , Interleucina-12/imunologia , Leucócitos Mononucleares/imunologia , Masculino , Pessoa de Meia-Idade , Proteínas com Domínio T/imunologia , Adulto Jovem
19.
Zhonghua Nan Ke Xue ; 11(11): 870-2, 2005 Nov.
Artigo em Chinês | MEDLINE | ID: mdl-16333969

RESUMO

OBJECTIVE: To explore the inhibitory effects of Niaoluqing, an oral liquid of traditional Chinese medicine, on the growth of urogenital chlamydia trachomatis (Ct). METHODS: Niaoluqing's applying concentration was 1 g/ml and 10 serologically untyped strains of Ct from the STD clinic were used. And the inhibitory effects of Niaoluqing on Ct was evaluated by McCoy cell microculture technique in vitro. RESULTS: Niaoluqing had inhibitory activity for urogenital Ct, and was capable of reducing inclusion numbers notably in the concentrations of 50 to 200 mg/ml. The number and volume of Ct inclusions reduced gradually and disappeared finally with the rising of the medicinal concentration. CONCLUSION: The traditional Chinese medicine Niaoluqing has inhibitory effects on the growth of urogenital Ct.


Assuntos
Chlamydia trachomatis/efeitos dos fármacos , Medicamentos de Ervas Chinesas/farmacologia , Chlamydia trachomatis/isolamento & purificação , Relação Dose-Resposta a Droga , Feminino , Humanos , Masculino , Testes de Sensibilidade Microbiana , Sistema Urogenital/microbiologia
20.
Di Yi Jun Yi Da Xue Xue Bao ; 25(8): 929-34, 2005 Aug.
Artigo em Chinês | MEDLINE | ID: mdl-16109543

RESUMO

OBJECTIVE: To identify the differentially expressed genes in systemic lupus erythematosus (SLE) by comparing the gene expression profiles of peripheral leukocytes between SLE patients and healthy controls. METHODS: The total RNA was extracted from 5 ml peripheral blood of normal subjects and SLE patients, and reversely transcribed in cDNA templates to synthesize cDNA probes labeled for hybridization with the microarray. RESULTS: Totally 89 over- or under-expressed genes were identified in 9 SLE patients as compared with the controls. These genes included genes associated with cytokines and their receptors, immunity, cell signal transduction, protein transcription and synthesis, ion channel and transporters, cell apoptosis, DNA and RNA processing, and extracellular matrix etc. Clustering analysis showed that in spite of the individual diversity of the SLE patients, their gene expression profiles were strikingly similar. CONCLUSION: The differentially expressed genes screened with oligonucleotide DNA microarray technique may provide clues for exploring the pathogenesis and progression of SLE, and for identification of potential molecular markers for diagnosis and development of therapeutic drugs.


Assuntos
Perfilação da Expressão Gênica , Leucócitos/metabolismo , Lúpus Eritematoso Sistêmico/genética , Análise de Sequência com Séries de Oligonucleotídeos , Adulto , Análise por Conglomerados , Feminino , Humanos , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA